NCT02273531View on ClinicalTrials.gov

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2004

Conditions
Healthy
Interventions
DRUG

Asasantin ER, new formulation

DRUG

Asasantin ER, present commercial formulation

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02273531 - Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter